Inflammation Biomarkers and Alzheimer's Disease: A Pilot Study Using NULISAseq

Overview

Journal Alzheimers Dement (Amst)

Date 2025 Jan 31

PMID 39886321

Authors

Guglielmo Di Molfetta

Ilaria Pola

Kubra Tan

Richard Isaacson

Kaj Blennow

Nicholas J Ashton

Andrea L Benedet

Henrik Zetterberg

Affiliations

Soon will be listed here.

Abstract

Introduction: Increasing evidence links amyloid beta (Aβ) aggregation with inflammation. This pilot study investigated the use of an immunoassay panel to map biomarker changes in patients with Alzheimer's disease (AD). Furthermore, we evaluated the stability of protein quantification after multiple freeze-thaw cycles (FTCs).

Methods: The nucleic acid-linked immuno-sandwich assay (NULISA) inflammation panel measured 203 proteins in serum samples of individuals with ( = 31) and without ( = 31) AD pathology. Linear models, adjusted for age and sex, contrasted protein expression across groups.

Results: After multiple-testing adjustments, glial fibrillary acidic protein ( < 0.001) and S100A12 ( < 0.001) were significantly changed in the presence of AD pathology. Furthermore, they correlated with cerebrospinal fluid biomarkers (phosphorylated tau-181 [p-tau181], tau, and Aβ42). Additional markers were nominally changed between groups. Five FTCs caused minimal changes in measurements with the NULISA inflammation panel.

Discussion: Monitoring of inflammation in AD, using the 200-plex NULISA panel, demonstrates changes in peripherally circulating inflammation-related proteins. Contrary to previous reports, FTCs had minimal impact on the quantification of inflammatory markers.

Highlights: The novel nucleic acid-linked immuno-sandwich assay (NULISA) inflammation panel, which includes 200 protein biomarkers, was used.The panel was used for the first time in serum from patients with Alzheimer's disease (AD).The protein S100A12 was identified as a potential biomarker for AD.Inflammation markers were stable in up to five freeze-thaw cycles.

Citing Articles

Inflammation biomarkers and Alzheimer's disease: A pilot study using NULISAseq.

Di Molfetta G, Pola I, Tan K, Isaacson R, Blennow K, Ashton N Alzheimers Dement (Amst). 2025; 17(1):e70079.

PMID: 39886321 PMC: 11780250. DOI: 10.1002/dad2.70079.

References

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

Behl T, Kaur G, Sehgal A, Bhardwaj S, Singh S, Buhas C . Multifaceted Role of Matrix Metalloproteinases in Neurodegenerative Diseases: Pathophysiological and Therapeutic Perspectives. Int J Mol Sci. 2021; 22(3). PMC: 7866808. DOI: 10.3390/ijms22031413. View

Tournier B, Tsartsalis S, Ceyzeriat K, Garibotto V, Millet P . In Vivo TSPO Signal and Neuroinflammation in Alzheimer's Disease. Cells. 2020; 9(9). PMC: 7565089. DOI: 10.3390/cells9091941. View

Huang S, Wang Y, Guo J . Biofluid Biomarkers of Alzheimer's Disease: Progress, Problems, and Perspectives. Neurosci Bull. 2022; 38(6):677-691. PMC: 9206048. DOI: 10.1007/s12264-022-00836-7. View

Oeckl P, Anderl-Straub S, von Arnim C, Baldeiras I, Diehl-Schmid J, Grimmer T . Serum GFAP differentiates Alzheimer's disease from frontotemporal dementia and predicts MCI-to-dementia conversion. J Neurol Neurosurg Psychiatry. 2022; . DOI: 10.1136/jnnp-2021-328547. View

Simren J, Weninger H, Brum W, Khalil S, Benedet A, Blennow K . Differences between blood and cerebrospinal fluid glial fibrillary Acidic protein levels: The effect of sample stability. Alzheimers Dement. 2022; 18(10):1988-1992. PMC: 9826213. DOI: 10.1002/alz.12806. View

Benedet A, Mila-Aloma M, Vrillon A, Ashton N, Pascoal T, Lussier F . Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. JAMA Neurol. 2021; 78(12):1471-1483. PMC: 8524356. DOI: 10.1001/jamaneurol.2021.3671. View

Gomez-Nicola D, Fransen N, Suzzi S, Perry V . Regulation of microglial proliferation during chronic neurodegeneration. J Neurosci. 2013; 33(6):2481-93. PMC: 6619184. DOI: 10.1523/JNEUROSCI.4440-12.2013. View

Pascoal T, Benedet A, Ashton N, Kang M, Therriault J, Chamoun M . Microglial activation and tau propagate jointly across Braak stages. Nat Med. 2021; 27(9):1592-1599. DOI: 10.1038/s41591-021-01456-w. View

10.

Ismail R, Parbo P, Madsen L, Hansen A, Hansen K, Schaldemose J . The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer's disease: a longitudinal PET study. J Neuroinflammation. 2020; 17(1):151. PMC: 7203856. DOI: 10.1186/s12974-020-01820-6. View

11.

Liu C, Chu D, Kalantar-Zadeh K, George J, Young H, Liu G . Cytokines: From Clinical Significance to Quantification. Adv Sci (Weinh). 2021; 8(15):e2004433. PMC: 8336501. DOI: 10.1002/advs.202004433. View

12.

Ashton N, Janelidze S, Mattsson-Carlgren N, Binette A, Strandberg O, Brum W . Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer's trial selection and disease monitoring. Nat Med. 2022; 28(12):2555-2562. PMC: 9800279. DOI: 10.1038/s41591-022-02074-w. View

13.

Spanic Popovacki E, Babic Leko M, Langer Horvat L, Brgic K, Vogrinc Z, Boban M . Soluble TREM2 Concentrations in the Cerebrospinal Fluid Correlate with the Severity of Neurofibrillary Degeneration, Cognitive Impairment, and Inflammasome Activation in Alzheimer's Disease. Neurol Int. 2023; 15(3):842-856. PMC: 10366813. DOI: 10.3390/neurolint15030053. View

14.

. 2023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023; 19(4):1598-1695. DOI: 10.1002/alz.13016. View

15.

Strozyk D, Blennow K, White L, Launer L . CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 2003; 60(4):652-6. DOI: 10.1212/01.wnl.0000046581.81650.d0. View

16.

Rosen C, Andersson C, Andreasson U, Molinuevo J, Bjerke M, Rami L . Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease. Dement Geriatr Cogn Dis Extra. 2014; 4(2):297-304. PMC: 4164083. DOI: 10.1159/000362164. View

17.

Verberk I, Misdorp E, Koelewijn J, Ball A, Blennow K, Dage J . Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. Alzheimers Dement. 2021; 18(8):1484-1497. PMC: 9148379. DOI: 10.1002/alz.12510. View

18.

Chen S, Chen S, Sun Y, Xu Z, Wang Y, Yao S . Fibroblast growth factor 21 ameliorates neurodegeneration in rat and cellular models of Alzheimer's disease. Redox Biol. 2019; 22:101133. PMC: 6383137. DOI: 10.1016/j.redox.2019.101133. View

19.

Pereira J, Janelidze S, Smith R, Mattsson-Carlgren N, Palmqvist S, Teunissen C . Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease. Brain. 2021; 144(11):3505-3516. PMC: 8677538. DOI: 10.1093/brain/awab223. View

20.

Bhatnagar B, Bogner R, Pikal M . Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm Dev Technol. 2007; 12(5):505-23. DOI: 10.1080/10837450701481157. View